A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. 1990

T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
Infectious Disease Research Unit, Upjohn Company, Kalamazoo, MI 49001.

A synthetic peptidemimetic substrate of the human immunodeficiency virus 1 (HIV-1) protease with a nonhydrolyzable pseudodipeptidyl insert at the protease cleavage site was prepared. The peptide U-81749 inhibited recombinant HIV-1 protease in vitro (inhibition constant Ki of 70 nanomolar) and HIV-1 replication in human peripheral blood lymphocytes (inhibitory concentration IC50 of 0.1 to 1 micromolar). Moreover, 10 micromolar concentrations of U-81749 significantly inhibited proteolysis of the HIV-1 gag polyprotein (p55) to the mature viral structural proteins p24 and p17 in cells infected with a recombinant vaccinia virus expressing the HIV-1 gag-pol genes. The HIV-1 like particles released from inhibitor-treated cells contained almost exclusively p55 and other gag precursors, but not p24. Incubation of HIV-like particles recovered from drug-treated cultures in drug-free medium indicated that inhibition of p55 proteolysis was at least partially reversible, suggesting that U-81749 was present within the particles.

UI MeSH Term Description Entries
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011498 Protein Precursors Precursors, Protein
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
January 1990, Disease markers,
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
June 2016, ACS medicinal chemistry letters,
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
March 2003, Journal of vascular surgery,
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
May 1995, Journal of virology,
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
August 2011, Retrovirology,
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
March 2014, Journal of acquired immune deficiency syndromes (1999),
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
October 2019, Biochemical and biophysical research communications,
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
October 1992, Biochemical and biophysical research communications,
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
September 2003, Journal of acquired immune deficiency syndromes (1999),
T J McQuade, and A G Tomasselli, and L Liu, and V Karacostas, and B Moss, and T K Sawyer, and R L Heinrikson, and W G Tarpley
September 2004, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!